224 related articles for article (PubMed ID: 26862853)
1. Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines.
Koss B; Ryan J; Budhraja A; Szarama K; Yang X; Bathina M; Cardone MH; Nikolovska-Coleska Z; Letai A; Opferman JT
Oncotarget; 2016 Mar; 7(10):11500-11. PubMed ID: 26862853
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma.
Turner BC; Eves T; Refaeli Y
DNA Cell Biol; 2008 Mar; 27(3):133-42. PubMed ID: 18163880
[TBL] [Abstract][Full Text] [Related]
3. Binding affinity of pro-apoptotic BH3 peptides for the anti-apoptotic Mcl-1 and A1 proteins: Molecular dynamics simulations of Mcl-1 and A1 in complex with six different BH3 peptides.
Modi V; Sankararamakrishnan R
J Mol Graph Model; 2017 May; 73():115-128. PubMed ID: 28279820
[TBL] [Abstract][Full Text] [Related]
4. A novel BH3 mimetic S1 potently induces Bax/Bak-dependent apoptosis by targeting both Bcl-2 and Mcl-1.
Zhang Z; Song T; Zhang T; Gao J; Wu G; An L; Du G
Int J Cancer; 2011 Apr; 128(7):1724-35. PubMed ID: 20503275
[TBL] [Abstract][Full Text] [Related]
5. BH3 mimetic-elicited Ca
Ferdek PE; Jakubowska MA; Nicolaou P; Gerasimenko JV; Gerasimenko OV; Petersen OH
Cell Death Dis; 2017 Mar; 8(3):e2640. PubMed ID: 28252652
[TBL] [Abstract][Full Text] [Related]
6. Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies.
Jullien M; Gomez-Bougie P; Chiron D; Touzeau C
Cells; 2020 Mar; 9(3):. PubMed ID: 32183335
[TBL] [Abstract][Full Text] [Related]
7. BH3 mimetics inhibit growth of chondrosarcoma--a novel targeted-therapy for candidate models.
Morii T; Ohtsuka K; Ohnishi H; Mochizuki K; Yoshiyama A; Aoyagi T; Hornicek FJ; Ichimura S
Anticancer Res; 2014 Nov; 34(11):6423-30. PubMed ID: 25368242
[TBL] [Abstract][Full Text] [Related]
8. Pro-apoptotic activity of BH3-only proteins and BH3 mimetics: from theory to potential cancer therapy.
Hartman ML; Czyz M
Anticancer Agents Med Chem; 2012 Oct; 12(8):966-81. PubMed ID: 22263800
[TBL] [Abstract][Full Text] [Related]
9. BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics.
Villalobos-Ortiz M; Ryan J; Mashaka TN; Opferman JT; Letai A
Cell Death Differ; 2020 Mar; 27(3):999-1007. PubMed ID: 31332296
[TBL] [Abstract][Full Text] [Related]
10. BH3 mimetics induce apoptosis independent of DRP-1 in melanoma.
Mukherjee N; Strosnider A; Vagher B; Lambert KA; Slaven S; Robinson WA; Amato CM; Couts KL; Bemis JGT; Turner JA; Norris DA; Shellman YG
Cell Death Dis; 2018 Sep; 9(9):907. PubMed ID: 30185782
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition.
Song T; Chai G; Liu Y; Xie M; Chen Q; Yu X; Sheng H; Zhang Z
Eur J Pharm Sci; 2015 Apr; 70():64-71. PubMed ID: 25596561
[TBL] [Abstract][Full Text] [Related]
12. Development of Noxa-like BH3 mimetics for apoptosis-based therapeutic strategy in chronic lymphocytic leukemia.
Billard C
Mol Cancer Res; 2012 Jun; 10(6):673-6. PubMed ID: 22466256
[TBL] [Abstract][Full Text] [Related]
13. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Small Molecule Bak Activator for Lung Cancer Therapy.
Park D; Anisuzzaman ASM; Magis AT; Chen G; Xie M; Zhang G; Behera M; Sica GL; Ramalingam SS; Owonikoko TK; Deng X
Theranostics; 2021; 11(17):8500-8516. PubMed ID: 34373755
[No Abstract] [Full Text] [Related]
15. BH3 mimetics: status of the field and new developments.
Billard C
Mol Cancer Ther; 2013 Sep; 12(9):1691-700. PubMed ID: 23974697
[TBL] [Abstract][Full Text] [Related]
16. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; FoĆ R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
17. New dimension in therapeutic targeting of BCL-2 family proteins.
Besbes S; Mirshahi M; Pocard M; Billard C
Oncotarget; 2015 May; 6(15):12862-71. PubMed ID: 25970783
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.
Karpel-Massler G; Ishida CT; Bianchetti E; Shu C; Perez-Lorenzo R; Horst B; Banu M; Roth KA; Bruce JN; Canoll P; Altieri DC; Siegelin MD
Cancer Res; 2017 Jul; 77(13):3513-3526. PubMed ID: 28522750
[TBL] [Abstract][Full Text] [Related]
19. A comparison of two strategies for affinity maturation of a BH3 peptide toward pro-survival Bcl-2 proteins.
Zhang S; Long A; Link AJ
ACS Synth Biol; 2012 Mar; 1(3):89-98. PubMed ID: 23651073
[TBL] [Abstract][Full Text] [Related]
20. BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells.
Butterworth M; Pettitt A; Varadarajan S; Cohen GM
Br J Cancer; 2016 Mar; 114(6):638-41. PubMed ID: 26954718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]